Cell line · CVCL_0077
Papers36
1 to 20 of 36
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia-driven transcriptional activation of MIR100HG by HIF-1α contributes to adaptive gene regulation in hepatocellular carcinoma. | Funct Integr Genomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Peptide‑based therapeutics targeting the SLC39A14‑PIWIL2 fusion in hepatocellular carcinoma. | Genomics Inform | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Menin-MLL1 complex cooperates with NF-Y to promote hepatocellular carcinoma survival. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/β-catenin signaling and tumor growth. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Improved approaches to channel capacity estimation discover compromised GPCR signaling in diverse cancer cells. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Macrophage CD5L is a target for cancer immunotherapy. | EBioMedicine | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. | Elife | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress. | Front Oncol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Spindle and kinetochore-associated complex subunit 3 (SKA3) promotes stem cell-like properties of hepatocellular carcinoma cells through activating Notch signaling pathway. | Ann Transl Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. | Nat Metab | 2020 | Its Methods give the RRID and name the line | PubMed | |
| A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed | |
| A Pharmacogenomic Landscape in Human Liver Cancers. | Cancer Cell | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0077/papers